What are second‑generation cephalosporins, including their common agents, dosing regimens, indications, and contraindications?

Second-Generation Cephalosporins: Overview and Clinical Use

Second-generation cephalosporins are beta-lactam antibiotics with enhanced gram-negative coverage compared to first-generation agents while maintaining reasonable gram-positive activity, with cefuroxime being the most clinically important agent in this class.

Common Agents

The primary second-generation cephalosporins include:

• Cefuroxime - The most widely used and first commercially available second-generation cephalosporin, available in both IV (cefuroxime sodium) and oral (cefuroxime axetil) formulations 1, 2
• Cefonicid - Longer-acting agent with superior pharmacokinetic characteristics 1
• Ceforanide - Another longer-acting alternative 1
• Cefoxitin - Often grouped with second-generation agents, though has distinct anti-anaerobic activity 3
• Cefazolin - Sometimes classified as first-generation but mentioned in combination regimens 3

Antimicrobial Spectrum

Second-generation cephalosporins demonstrate:

• Gram-positive coverage: Generally less active against gram-positive cocci than first-generation cephalosporins 1
• Gram-negative coverage: Enhanced activity against Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Moraxella catarrhalis, and Salmonella/Shigella species 2
• Beta-lactamase stability: Cefuroxime is the most active cephalosporin against beta-lactamase-producing Haemophilus influenzae 1
• Staphylococcus aureus: Active against methicillin-sensitive strains only 2

Dosing Regimens

Cefuroxime Axetil (Oral)

• Standard infections: 250 mg twice daily 2
• Urinary tract infections: 125 mg twice daily may be effective 2
• Severe lower respiratory tract infections/pneumonia: 500 mg twice daily 2
• Uncomplicated gonorrhea: Single 1 g dose 2
• Bioavailability: 68% when taken with food; maximum plasma concentrations of 4.6 mg/L (250 mg dose) and 7.9 mg/L (500 mg dose) 2

Cefuroxime IV

• Perioperative prophylaxis: 1.5 g one hour prior to surgery, then 1.5 g every 12 hours for 3 additional doses 4, 5
• General dosing: 1.5-2 g, with single doses providing adequate serum levels for approximately 3 hours 5

Clinical Indications

Respiratory Tract Infections

• Lower respiratory tract: Acute and chronic bronchitis, pneumonia 2
• Upper respiratory tract: Otitis media, sinusitis, tonsillitis, pharyngitis 2
• Coverage: Highly effective against Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis 2

Urinary Tract Infections

• Pyelonephritis, cystitis, urethritis 2
• Similar efficacy to third-generation cephalosporins in pyelonephritis (71.9% vs 76.0% sensitivity, not statistically significant) 6

Intra-Abdominal Infections

• Mild to moderate infections: Cefuroxime combined with metronidazole is recommended as combination therapy by major guidelines 3
• Note: WHO guidelines from 2024 consider cefuroxime redundant compared to ceftriaxone due to narrower gram-negative coverage, preferring cefotaxime or ceftriaxone instead 3

Genitourinary Infections

• Gonorrhea (acute uncomplicated gonococcal urethritis and cervicitis) 2

Skin and Soft Tissue Infections

• Furunculosis, pyoderma, impetigo 2

Surgical Prophylaxis

• Appropriate spectrum: Covers Staphylococcus spp., Streptococcus spp., and Escherichia coli, the most frequent surgical pathogens 5
• Colorectal surgery: Must be combined with anti-anaerobic agent 5
• Cardiac surgery: Cefuroxime showed equivalent efficacy to cefazolin (2.9% vs 2.1% chest wound infections, p=0.79) 4
• Duration: Single-dose prophylaxis appears adequate for procedures under 3 hours; prolonged procedures require additional dosing 5

Pediatric Meningitis

• Cefuroxime has received approval for common pediatric bacterial meningitis infections 1

Contraindications and Precautions

Absolute Contraindications

• Severe beta-lactam allergy: Patients with documented severe allergic reactions to cephalosporins or penicillins 2

Relative Contraindications and Warnings

• Staphylococcal infections: Failures with cefonicid have been reported in treating staphylococcal infections 1
• Resistance monitoring: Clinicians must remain alert for development of bacterial resistance or decreased efficacy 1
• Protein binding: Cefuroxime has 33% protein binding, which may affect dosing in certain clinical scenarios 2

Adverse Effects

Adverse reactions are generally mild and transient, including:

• Gastrointestinal disturbances (most common) 2
• Diarrhea 2
• Nausea and vomiting 2

Resistance Considerations

Emerging Resistance Patterns

• Recent data (2026): Exposure to second-generation cephalosporins led to higher increases in resistance to all cephalosporins compared to amoxicillin-clavulanate in subsequent urinary isolates 7
• Cross-resistance: Second-generation cephalosporins were associated with higher third-generation cephalosporin resistance compared to fluoroquinolones (risk difference -2.1%, 95% CI -3.9 to -0.4) 7
• Historical stability: During the 1990s-early 2000s, no major resistance development was observed against second-generation cephalosporins 5

Clinical Implications

• Community-acquired infections: Resistance rates remain lower than nosocomial infections 8
• Institutional antibiograms: Local resistance patterns should guide selection between first-, second-, and third-generation agents 4

Pharmacokinetic Advantages

The primary advantage of newer second-generation agents (cefonicid, ceforanide, cefuroxime) over older alternatives is superior pharmacokinetics, allowing:

• Smaller doses 1
• Longer dosing intervals 1
• Potential reduction in total drug costs 1
• Adequate tissue penetration in interstitial fluid, bronchial mucosa, tonsils, and bronchial secretions 2

Key Clinical Pitfalls

• Anaerobic coverage: Second-generation cephalosporins lack adequate anaerobic coverage; always combine with metronidazole for intra-abdominal or colorectal surgical prophylaxis 3, 5
• Enterococcal coverage: Most second-generation agents do not adequately cover enterococcus; ampicillin must be added when enterococcal coverage is needed 3
• MRSA: No activity against methicillin-resistant Staphylococcus aureus; vancomycin required if MRSA suspected 3, 2
• Extended-spectrum beta-lactamases (ESBL): Second-generation cephalosporins are not appropriate for infections with ESBL-producing organisms 3